EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species

Lisa K Ryan iD, Isabella M Griffiths, Uyen Emily Do, Denny Gao iD, Erika L Figgins, Kristian Sørensen iD, Jennifer S Lin iD, Natalia Molchanova iD, Kent Kirshenbaum, Annelise E Barron iD, Gill Diamond iD

ACS Infectious Diseases · 09.10.2026 · 12 (10) · 3462-3471

DOI: 10.1021/acsinfecdis.6c00525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 04.09.2026. Verfasst von Lisa K Ryan und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Louisville Center for Predictive Medicine , Louisville, Kentucky40202, United States. Hauptthemen laut MEDLINE: Antifungal Agents, Peptoids, Candida, Candida auris. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lifespan Research Institute, Stanford University, Dr. James J. Truchard and the Truchard Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive candidiasis is a serious fungal infection caused by Candida species that can enter the bloodstream and affect major organs, particularly in immunocompromised patients. Development of resistance to standard antifungal therapies, especially with C. auris, has become a major public health issue. While antimicrobial peptides such as the human cathelicidin, LL-37, could represent a possible therapeutic strategy, they are often inactivated when delivered systemically. One alternative therapeutic strategy is antimicrobial peptoids. We studied in vitro activity of three peptoid compounds, oligomers of N-substituted glycines, which mimic the activity of LL-37. Our aim was to establish these peptoid compounds as a potential treatment of invasive candidiasis and compare them to LL-37′s antifungal activity. In vitro, LL-37 did not exhibit antifungal activity (MIC > 64) against all C. auris strains and three species of Candida. In contrast, three peptoids were tested against ten C. auris strains and six other Candida species and showed good activity. MICs measured as low as 4 μg/mL for TM5 against C. auris strain 381. Mechanistic studies using TEM and fluorescent confocal microscopy of peptoids against C. auris clinical isolates showed membrane disruption and consolidation of organelles. Peptoids TM4 and TM5 showed strong synergistic effects with fluconazole and caspofungin, and amphotericin B. Serial daily passage of TM4 and TM5 at sub-MIC concentrations showed no resistance developing for up to 3 weeks. Fungicidal kinetics revealed complete killing of fungal colonies after around 1 h. A systemic candidiasis mouse model treated subcutaneously with TM5 3 h after C. auris infection resulted in clearing of infection, indicated by colony forming units (cfu) per gram of kidney, at 24 h with the 5 mg/kg dose. This demonstrates that antimicrobial peptoids are active systemically and have potential to be an antifungal treatment for candidemia, particularly as an alternative therapy for resistant strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsPeptoidsCandidaCandida aurisCandidiasisAnimalsMicrobial Sensitivity TestsMiceHumansFemale

Stichwörter der Autor:innen

antifungalcandidemianonalbicanspeptoidsynergy

Substanzen

Antifungal AgentsPeptoids

Autor:innen und Institutionen

  • University of Louisville Center for Predictive Medicine , Louisville, Kentucky40202, United States.
  • Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, Kentucky40202, United States.
  • Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, Florida32608, United States.
  • Department of Bioengineering, Stanford University Schools of Medicine and Engineering, Stanford, California94305, United States.
  • Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California94720, United States.
  • Department of Chemistry, New York University, New York, New York10003, United States.

ORCID-Profile: Lisa K Ryan, Denny Gao, Kristian Sørensen, Jennifer S Lin, Natalia Molchanova, Annelise E Barron, Gill Diamond

Förderung

  • Lifespan Research Institute
  • Stanford University
  • Dr. James J. Truchard and the Truchard Foundation
  • NIA NIH HHS
  • Cisco University Research Program Fund
  • Basic Energy Sciences
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Ryan, L. K., Griffiths, I. M., Do, U. E., Gao, D., Figgins, E. L., Sørensen, K., Lin, J. S., Molchanova, N., Kirshenbaum, K., Barron, A. E., & Diamond, G. (2026). Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species. ACS Infectious Diseases, 12(10), 3462-3471. https://doi.org/10.1021/acsinfecdis.6c00525

Vancouver

Ryan LK, Griffiths IM, Do UE, Gao D, Figgins EL, Sørensen K, et al. Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species. ACS Infectious Diseases. 2026;12(10):3462-3471. doi:10.1021/acsinfecdis.6c00525

BibTeX
@article{Ryan2026,
  author = {Ryan, Lisa K and Griffiths, Isabella M and Do, Uyen Emily and Gao, Denny and Figgins, Erika L and Sørensen, Kristian and Lin, Jennifer S and Molchanova, Natalia and Kirshenbaum, Kent and Barron, Annelise E and Diamond, Gill},
  title = {Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {10},
  pages = {3462--3471},
  doi = {10.1021/acsinfecdis.6c00525}
}
Kostenlos starten →